Authors
Latest:
Dr Wen on the Evaluation of Vorasidenib in IDH1- and IDH2-Mutated Low-Grade GliomaPatrick Y. Wen, MD, discusses the evaluation of vorasidenib in IDH1- and IDH2-mutated low-grade glioma, as evaluated in the phase 3 INDIGO trial.
Latest:
Dr Olivares on the Functional Advantages of Focal Therapy in Prostate CancerRuben Olivares, MD, discusses the functional advantages of using focal therapy over localized radiation in prostate cancer.
Latest:
Dr Waks on Ongoing Research in Residual HER2+ Breast CancerAdrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.
Latest:
CLL: Final ThoughtsAn expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Latest:
Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCLWilliam B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.
Latest:
Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast CancerNuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.
Latest:
Dr Davis on the Utility of ADCs in Breast CancerAndrew Davis, MD, discusses the use of antibody-drug conjugates in breast cancer, highlighting recent updates with these agents in the treatment paradigm.
Latest:
Dissecting Immunotherapy Options for TNBCMargaret Gatti-Mays MD, MPH, of The James Cancer Hospital at Ohio State University, discusses the available immunotherapy options in triple-negative breast cancer.
Latest:
Review of AENEAS Trial and Similar AgentsExperts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.
Latest:
Advanced Biliary Tract Cancers: Novel Biomarker StrategiesClosing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Latest:
Dr Sokolova on the Importance of Genetic Testing in Prostate CancerAlexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.
Latest:
Dr. Nassif on Examining Gut Microbial Signatures in the Tumor MicroenvironmentElise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.
Latest:
Dr Wolf on Challenges Conducting Clinical Trials Evaluating Surgery in MesotheliomaAndrea Wolf, MD, MPH, discusses challenges experienced when conducting randomized trials to assess the role of surgery in mesothelioma management.
Latest:
Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPCThe addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.
Latest:
Dr Sahin on the Design of the Northstar Response Assay in Advanced GI CancerIlyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.
Latest:
Dr. Moon on the Future of Care in Prostate CancerHelen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.
Latest:
Practical Considerations for Fellows Treating VTEMost hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.
Latest:
Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCCMichael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.
Latest:
Oral Oncolytics Will Require Health Care System to AdaptJudging from the drug pipeline, the future of oncology is oral chemotherapy.
Latest:
Dr DiPasquale on the Continued Investigation into Cerianna PET Scans in Breast CancerAllison A. DiPasquale, MD, discusses the continued evaluation of Cerianna positron emission tomography scans in patients with breast cancer and highlights the need for a multidisciplinary approach when treating patients in this population.
Latest:
Dr. Costa on the Implications of the KEYNOTE-522 Trial in TNBCRicardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.
Latest:
Monitoring Patients for Interstitial Lung DiseaseExperts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.
Latest:
Management of Hepatocellular Carcinoma: Future Directions in CareExpert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.
Latest:
Dr. Saenz on the Need for Ongoing Research Efforts in Cervical CancerCheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.
Latest:
Dr. Rana on Using Age at Diagnosis to Guide the Utility of Genetic Testing in Prostate CancerHuma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.
Latest:
Providing Timely Cancer Care Access Is Crucial Amid Growing Patient VolumeA closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.
Latest:
Dr Walker-Mimms on Outcomes With Filanesib in Ewing and Clear Cell SarcomaHannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.
Latest:
Dr Borthakur on the SELECT MDS-1 Trial in Newly Diagnosed MDSGautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.
.jpg?fit=crop&auto=format)
